MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials

Nature Reviews Neurology

Volumn 8, Issue 1, 2012, Pages 13-21

  Barkhof, Frederik ^a   Simon, Jack H ^b   Fazekas, Franz ^c   Rovaris, Marco ^d   Kappos, Ludwig ^e   De Stefano, Nicola ^f   Polman, Chris H ^a   Petkau, John ^g   Radue, Ernst W ^e   Sormani, Maria P ^h   Li, David K ^g   O'Connor, Paul ⁱ   Montalban, Xavier ^j   Miller, David H ^k   Filippi, Massimo ^l  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f UNIVERSITY OF SIENA   (Italy)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l SAN RAFFAELE HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM;

BRAIN RADIOGRAPHY; CERVICAL SPINE RADIOGRAPHY; CLINICAL EFFECTIVENESS; CLINICALLY ISOLATED SYNDROME; CONTRAST SENSITIVITY; DISEASE MARKER; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROMONITORING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT SAFETY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RADIATION SAFETY; RADIOFREQUENCY RADIATION; REVIEW; SIGNAL PROCESSING;

CLINICAL TRIALS AS TOPIC; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOMODULATION; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RESEARCH DESIGN;

EID: 84655162283     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2011.190     Document Type: Review

References (79)

1. Miller, D. H. et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted action guidelines. J. Neurol. Neurosurg. Psychiatry 54, 683-688 (1991).
2. Miller, D. H. et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann. Neurol. 39, 6-16 (1996). (Pubitemid 26052212)
3. Miller, D. H. et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15-23 (2003). (Pubitemid 36026342)
4. O'Connor, P. W. et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66, 894-900 (2006). (Pubitemid 43739766)
5. Kappos, L. et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355, 1124-1140 (2006). (Pubitemid 44394919)
6. Kappos, L. et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372, 1463-1472 (2008).
7. Wynn, D. et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 9, 381-390 (2010).
8. Polman, C. H. et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64, 987-991 (2005).
9. Hauser, S. L. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676-688 (2008). (Pubitemid 351240747)
10. van Oosten, B. W. et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47, 1531-1534 (1996). (Pubitemid 26422549)
11. [No authors listed] TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 53, 457-465 (1999).
12. Barkhof, F., van Waesberghe, J. H., Uitdehaag, B. M. & Polman, C. H. Ibuprofen does not suppress active multiple sclerosis lesions on gadolinium-enhanced MR images. Ann. Neurol. 42, 982 (1997). (Pubitemid 28008431)
13. Polman, C. H. et al. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: A double-blind randomized study. Mult. Scler. 9, 342-348 (2003).
14. Kappos, L., Barkhof, F. & Desmet, A. The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: Results from a randomised, controlled trial. J. Neurol. 252 (Suppl. 2), 46 (2005).
15. Segal, B. M. et al. Ustekinumab MS Investigators. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: A phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7, 796-804 (2008).
16. Filippi, M., Wolinsky, J. S., Comi, G. & CORAL Study Group. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: A multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol. 5, 213-220 (2006). (Pubitemid 43238344)
17. Fazekas, F. et al. MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Mult. Scler. 11, 433-440 (2005). (Pubitemid 40984238)
18. Barkhof, F. et al. Ibudilast in relapsing-remitting multiple sclerosis: A neuroprotectant? Neurology 74, 1033-1040 (2010).
19. Killestein, J. et al. Antibody-mediated suppression of Vß5.2/5.3+ T cells in multiple sclerosis: Results from an MRI-monitored phase II clinical trial. Ann. Neurol. 51, 467-474 (2002). (Pubitemid 34260776)
20. Polman, C. H. et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment. Neurology 70, 1134-1140 (2008). (Pubitemid 351464771)
21. O'Connor, P. et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study. Lancet Neurol. 8, 889-897 (2009).
22. Mikol, D. D. et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial. Lancet Neurol. 7, 903-914 (2008).
23. Inusah, S. et al. Assessing changes in relapse rates in multiple sclerosis. Mult. Scler. 16, 1414-1421 (2010).
24. Barkhof, F. & Filippi, M. MRI-the perfect surrogate marker for multiple sclerosis? Nat. Rev. Neurol. 5, 182-183 (2009).
25. Prentice, R. L. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat. Med. 8, 431-440 (1989). (Pubitemid 19105891)
26. Sormani, M. P. et al. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology 58, 417-421 (2002). (Pubitemid 34150916)
27. Sormani, M. P. et al. MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN ß-1b. Neurology 60, 1462-1466 (2003). (Pubitemid 36554807)
28. Sormani, M. P. et al. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Mult. Scler. 17, 541-549 (2011).
29. Petkau, J. et al. Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult. Scler. 14, 770-778 (2008).
30. Daniels, M. & Hughes, M. D. Meta-analysis for the evaluation of potential surrogate markers. Stat. Med. 16, 1965-1982 (1997). (Pubitemid 27397267)
31. Korn, E. L., Albert, P. S. & McShane, L. M. Assessing surrogates as trial endpoints using mixed models. Stat. Med. 24, 163-182 (2005). (Pubitemid 40124164)
32. Sormani, M. P. et al. Magnetic resonance imaging as a potential surrogate for relapses in MS: A meta-analytic approach. Ann. Neurol. 65, 268-275 (2009).
33. Sormani, M., Bonzano, L., Roccatagliata, L. & de Stefano, N. Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: Data on novel oral drugs. Mult. Scler. 17, 630-633 (2011).
34. Sormani, M. P. et al. Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. Neurology 75, 302-309 (2010).
35. Wattjes, M. P. & Barkhof, F. High field MRI in the diagnosis of multiple sclerosis: High field-high yield? Neuroradiology 51, 279-292 (2009).
36. Geurts, J. J. et al. Intracortical lesions in multiple sclerosis: Improved detection with 3D double inversion-recovery MR imaging. Radiology 236, 254-260 (2005). (Pubitemid 40853320)
37. Calabrese, M. et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch. Neurol. 64, 416-422 (2007).
38. Nelson, F. et al. Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. AJNR Am. J. Neuroradiol. 28, 1645-1649 (2007). (Pubitemid 47598132)
39. Moraal, B. et al. Multi-contrast, isotropic, single-slab 3D MR imaging in multiple sclerosis. Eur. Radiol. 18, 2311-2320 (2008).
40. Barkhof, F., Pouwels, P. J. & Wattjes, M. P. The Holy Grail in diagnostic neuroradiology: 3T or 3D? Eur. Radiol. 21, 449-456 (2011).
41. Bot, J. C. & Barkhof, F. Spinal-cord MRI in multiple sclerosis: Conventional and nonconventional MR techniques. Neuroimaging Clin. N. Am. 19, 81-99 (2009).
42. Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69, 292-302 (2011).
43. Thorpe, J. W. et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 46, 373-378 (1996). (Pubitemid 26081316)
44. Silver, N. C. et al. A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis. J. Neurol. 248, 215-224 (2001). (Pubitemid 32245498)
45. Losseff, N. A. et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119, 701-708 (1996). (Pubitemid 26237169)
46. Kalkers, N. F., Barkhof, F., Bergers, E., van Schijndel, R. & Polman, C. H. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: A pilot study. Mult. Scler. 8, 532-533 (2002). (Pubitemid 35396406)
47. Silver, N. C. et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 120, 1149-1161 (1997). (Pubitemid 27285734)
48. Comi, G. et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371, 2085-2092 (2008). (Pubitemid 351842581)
49. Dousset, V. et al. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. AJNR Am. J. Neuroradiol. 27, 1000-1005 (2006). (Pubitemid 44897675)
50. Vellinga, M. M. et al. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain 131, 800-807 (2008). (Pubitemid 351294725)
51. Barkhof, F. et al. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology. 49, 1682-1688 (1997). (Pubitemid 28015137)
52. Molyneux, P. D. et al. Visual analysis of serial T2-weighted MRI in multiple sclerosis: Intra- and interobserver reproducibility. Neuroradiology 41, 882-888 (1999). (Pubitemid 30000290)
53. Rovaris, M. et al. Multiple sclerosis: Interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images. J. Neurol. 246, 920-925 (1999). (Pubitemid 29512162)
54. Filippi, M. et al. Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology 50, 238-244 (1998). (Pubitemid 28106048)
55. Sled, J. G., Zijdenbos, A. P. & Evans, A. C. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging 17, 87-97 (1998). (Pubitemid 128742012)
56. Cocosco, C. A., Zijdenbos, A. P. & Evans, A. C. A fully automatic and robust brain MRI tissue classification method. Med. Image Anal. 7, 513-527 (2003). (Pubitemid 37327991)
57. Smith, S. M. et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 23 (Suppl. 1), S208-S219 (2004). (Pubitemid 39421720)
58. Horsfield, M. A. et al. Incorporating domain knowledge into the fuzzy connectedness framework: Application to brain lesion volume estimation in multiple sclerosis. IEEE Trans. Med. Imaging 26, 1670-17680 (2007).
59. Klein, A. et al. Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage 46, 786-802 (2009).
60. Moraal, B. et al. Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. Radiology 255, 154-163 (2010).
61. Moraal, B. et al. Long-interval T2-weighted subtraction magnetic resonance imaging: A powerful new outcome measure in multiple sclerosis trials. Ann. Neurol. 67, 667-675 (2010).
62. Barkhof, F., Calabresi, P. A., Miller, D. H. & Reingold, S. C. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat. Rev. Neurol. 5, 256-266 (2009).
63. Zivadinov, R. et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 71, 136-144 (2008).
64. Kapoor, R. et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 9, 681-688 (2010).
65. Miller, D. H. et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68, 1390-1401 (2007). (Pubitemid 46659091)
66. Zhao, Y., Traboulsee, A., Petkau, A. J. & Li, D. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis. Neurology 70, 1092-1097 (2008). (Pubitemid 351464765)
67. Sormani, M. P. et al. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: Implications for clinical trials. J. Neurol. Sci. 163, 74-80 (1999). (Pubitemid 29155420)
68. Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402-415 (2010).
69. Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387-401 (2010).
70. Barkhof, F. et al. Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology 65, 1447-1454 (2005). (Pubitemid 41552778)
71. Jacobs, L. D. et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 343, 898-904 (2000).
72. Barkhof, F. et al. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: Integrated 2-year results. Arch. Neurol. 64, 1292-1298 (2007). (Pubitemid 47403084)
73. Shellock, F. G. & Spinazzi, A. MRI safety update 2008: Part 1, MRI contrast agents and nephrogenic systemic fibrosis. AJR Am. J. Roentgenol. 191, 1129-1139 (2008). 74. Leiner, T. & Kucharczyk, W. NSF prevention in clinical practice: Summary of recommendations and guidelines in the United States, Canada, and Europe. J. Magn. Reson. Imaging 30, 1357-1363 (2009).
74. Yousry, T. A. et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354, 924-933 (2006).
75. Riddell, C. A. et al. Evaluation of safety monitoring guidelines based on MRI lesion activity in multiple sclerosis. Neurology (in press).
76. Hawker, K. et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 66, 460-471 (2009).
77. Miller, D. H. et al. Effect of interferon-ß1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-ß1b in secondary progressive multiple sclerosis. Ann. Neurol. 46, 850-859 (1999).
78. Barkhof, F. et al. T1-hypointense lesions in secondary progressive multiple sclerosis: Effect of interferon beta-1b treatment. Brain 124, 1396-1402 (2001). (Pubitemid 32606100)
79. Hartung, H. P. & Aktas, O. Evolution of multiple sclerosis treatment: Next generation therapies meet next generation efficacy criteria. Lancet Neurol. 10, 293-295 (2011).